Today, Cellectis SA (CLLS) PT Set at $41.00 by Piper Jaffray Cos.

Today, Cellectis SA (CLLS) PT Set at $41.00 by Piper Jaffray Cos.

Cellectis SA (NASDAQ:CLLS) has been assigned a $41.00 price target by equities research analysts at Piper Jaffray Cos. in a research report issued on Thursday. The firm presently has a “buy” rating on the stock. Piper Jaffray Cos.’s target price indicates a potential upside of 127.15% from the company’s previous close.

A number of other research firms also recently issued reports on CLLS. Zacks Investment Research downgraded Cellectis SA from a “buy” rating to a “hold” rating in a research note on Friday, October 21st. Oppenheimer Holdings Inc. restated an “outperform” rating and issued a $65.00 target price on shares of Cellectis SA in a research note on Wednesday, September 14th. Finally, Jefferies Group restated a “buy” rating on shares of Cellectis SA in a research note on Friday, August 5th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $42.33.

Cellectis SA (NASDAQ:CLLS) traded up 3.68% during trading on Thursday, reaching $18.05. The company’s stock had a trading volume of 92,198 shares. Cellectis SA has a 12 month low of $16.35 and a 12 month high of $34.99. The stock’s 50 day moving average is $18.85 and its 200 day moving average is $25.20.

Several institutional investors have recently made changes to their positions in the company. Lazard Asset Management LLC increased its position in shares of Cellectis SA by 3.7% in the third quarter. Lazard Asset Management LLC now owns 285,175 shares of the company’s stock worth $6,867,000 after buying an additional 10,120 shares during the last quarter. Susquehanna International Group LLP acquired a new position in shares of Cellectis SA during the third quarter worth $281,000. HighTower Advisors LLC increased its position in shares of Cellectis SA by 0.9% in the third quarter. HighTower Advisors LLC now owns 13,565 shares of the company’s stock worth $327,000 after buying an additional 125 shares during the last quarter. Morgan Stanley increased its position in shares of Cellectis SA by 1,034.6% in the third quarter. Morgan Stanley now owns 64,817 shares of the company’s stock worth $1,561,000 after buying an additional 59,104 shares during the last quarter. Finally, BlackRock Institutional Trust Company N.A. acquired a new position in shares of Cellectis SA during the third quarter worth $419,000. Hedge funds and other institutional investors own 20.02% of the company’s stock.

Cellectis SA Company Profile

Related posts

Leave a Comment